Marta Kamieniak

Dr. Marta Kamieniak


Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
MDMARIA DIMOU
MARIA DIMOU
MSMatthaios Speletas
Matthaios Speletas
Cinzia MilitoCinzia Milito
Cinzia Milito
APAleksandra Pyzik
Aleksandra Pyzik
DHDörte Huscher
Dörte Huscher
MBMichael Borte
Michael Borte
The Facilitated Immunoglobulin Administration Registry And Outcomes (FIGARO) Study was a European, multicenter, prospective, observational study conducted across Europe designed to provide insights on the clinical use and tolerability of facilitated subcutaneous immunoglobulin (fSCIG). Data herein are reported for the cohort of patients with secondary immunodeficiency (SID), with a subgroup analysis by age. The SID cohort included 31 patients: 1 pediatric, 15 adult, and 15 older adult patients. Over the 36-month observation period, the median monthly dose of fSCIG (30 g) and median monthly infusion volume per patient (300 mL) remained constant in both adult-age cohorts. Serum trough levels tended to increase over time. Most patients required only one infusion site and could receive the full dose every 3–4 weeks. There was a trend toward self-administration at home. In the adult group, infusion site inflammation and headache were reported at the inclusion visit (n = 1 each), with no adverse drug reactions reported at any of the follow-up visits. No acute severe bacterial infections were reported during the study follow-up. These results demonstrate the feasibility and tolerability of fSCIG use in patients with SID and the flexibility of administration settings including self-administration at home in patients aged ≥65 years.

12 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MDMARIA DIMOU
MARIA DIMOU
AVAngelo VACCA
Angelo VACCA
SSSilvia Sánchez-Ramón
Silvia Sánchez-Ramón
EKEwa Karakulska-Prystupiuk
Ewa Karakulska-Prystupiuk
VLVikte Lionikaite
Vikte Lionikaite
MKMarta Kamieniak
Marta Kamieniak
Background: Secondary immunodeficiency disease (SID) is a complex, heterogeneous condition that occurs when extrinsic factors weaken the immune system. Expert consensus guidelines recommend immunoglobulin replacement therapy to manage immunoglobulin G (IgG) levels and mitigate severe, recurrent, and persistent infections. Hyaluronidase-facilitated subcutaneous immunoglobulin (fSCIG) 10% is a dual-vial unit of IgG and recombinant human hyaluronidase; the latter enables absorption of higher volumes of IgG than conventional subcutaneous therapies. Methods: For this systematic literature review, Embase, MEDLINE®, and the Cochrane Library were searched on 9 August 2023, with supplemental congress searches. Results: Eight studies fulfilled the inclusion criteria, reporting real-world evidence of the clinical effectiveness, safety, and tolerability of fSCIG 10% in 183 patients with SID in Europe from September 2014 to August 2021. The potential causes of SID were primarily hematological malignancies, most commonly chronic lymphocytic leukemia. Treatment was typically administered at 4-week or 3-week intervals, with doses of approximately 0.4 g/kg/month. Infections were rare during follow-up, with numerical reductions observed after fSCIG 10% treatment initiation compared with the period before initiation. Adverse reactions, including local infusion site reactions, and tolerability events were uncommon. Conclusions: Given the recency of fSCIG 10% use in patients with SID, there are opportunities for future research to better understand survival and patient-reported outcomes after receiving this treatment. Despite SID heterogeneity, this study demonstrates the feasibility of fSCIG 10% treatment for this condition.

12 September 2024 in Annals of Hematology
Verified
Journal Article
Open access
PDF file
CSCsaba Siffel
Csaba Siffel
JRJoshua Richter
Joshua Richter
CAColin Anderson-Smits
Colin Anderson-Smits
MKMarta Kamieniak
Marta Kamieniak
KRKaili Ren
Kaili Ren
MDMatthew S. Davids
Matthew S. Davids
Patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and secondary immunodeficiency disease (SID) are susceptible to severe, recurrent, or persistent infections. This retrospective cohort study assessed the burden of infection in patients with CLL/SLL with and without SID, and in immunoglobulin replacement therapy (IgRT)-treated and -untreated patients with CLL/SLL and SID. Anonymized data from the US Optum-Humedica database (Oct-1-2015–Mar-10-2020) were used. Eligible patients aged ≥ 18 years with a confirmed CLL/SLL diagnosis were assigned to cohorts (SID or no-SID) using an algorithm based on serum IgG levels < 5.0 g/L, hypogammaglobulinemia diagnosis codes, and ≥ 1 major infection. A further sub-categorization was made based on patients with SID who received IgRT and those who did not. During 12-month follow-up, patients with CLL/SLL and SID were significantly more likely to experience infections (70.1% vs. 30.4%), including severe bacterial infections (39.8% vs. 9.2%), and infections requiring hospitalization (27.7% vs. 5.8%) than patients without SID. The use of anti-infectives and healthcare resource utilization (HCRU) was also higher in the SID cohort versus the no-SID cohort. Overall survival was shorter in patients with SID than those without (12.3 vs. 16.9 months). In patients with CLL/SLL and SID, burden of infection and HCRU were greater in IgRT-treated patients than in no-IgRT patients, potentially highlighting the IgRT-treated cohort as a more vulnerable population. Increasing understanding of SID burden may help to improve outcomes in patients with CLL/SLL. Further research is needed to develop guidance for IgRT use and to assess the benefits of IgRT in this vulnerable population.

17 June 2024 in Journal of Medical Virology
Verified
Journal Article
Open access
MKMichael Karbiener
Michael Karbiener
GKGerhard Kindle
Gerhard Kindle
IMIsabelle Meyts
Isabelle Meyts
MSMikko R. J. Seppänen
Mikko R. J. Seppänen
FCFabio Candotti
Fabio Candotti
Raphael SchmittRaphael Schmitt
Raphael Schmitt
Immunocompromised individuals are at significantly elevated risk for severe courses of coronavirus disease 2019 (COVID‐19). In addition to vaccination, severe acute respiratory syndrome coronavirus 2 ( SARS‐CoV‐2 ) neutralizing antibodies (nAbs) have been applied throughout the pandemic, with time of treatment onset and potency against the currently prevailing virus variant identified as relevant factors for medical benefit. Using data from the European Society for Immunodeficiencies (ESID) registry, the present study evaluated COVID‐19 cases in three groups of patients with inborn errors of immunity (IEI; 981 agammaglobulinemia patients on immunoglobulin replacement therapy (IGRT); 8960 non‐agammaglobulinemia patients on IGRT; 14 428 patients without IGRT), and the neutralizing capacity of 1100 immunoglobulin lots against SARS‐CoV‐2 (“Wuhan” and Omicron strains), throughout 3 years. From the first (2020/2021) to the second (2021/2022) cold season, i.e., during the virus drift to the more contagious Omicron variants, an increase in case numbers was recorded that was comparable (~2‐ to 3‐fold) for all three study groups. During the same period, immunoglobulin lots showed a profound nAb increase against the archetypal SARS‐CoV‐2 strain, yet only low levels of Omicron nAbs. Notably, shortly before the third (2022/2023) cold season, Omicron ‐neutralizing capacity of released immunoglobulin lots had plateaued at high levels. From the second to the third cold season, COVID‐19 cases dropped markedly. While a ~6‐fold case reduction was recorded for the groups of non‐agammaglobulinemia patients on IGRT and IEI patients not receiving IGRT, the decline was ~30‐fold for the group of agammaglobulinemia patients on IGRT. These findings suggest a substantial COVID‐19‐protective effect of IGRT, at least for distinct groups of antibody‐deficient patients.

10 April 2024 in Clinical Lymphoma Myeloma and Leukemia
Verified
Journal Article
Open access
JRJoshua Richter
Joshua Richter
MDMatthew S. Davids
Matthew S. Davids
CAColin Anderson-Smits
Colin Anderson-Smits
MKMarta Kamieniak
Marta Kamieniak
KRKaili Ren
Kaili Ren
CSCsaba Siffel
Csaba Siffel
This retrospective cohort study compared patient characteristics and burden of infection in patients with mature B cell malignancies with and without secondary immunodeficiency disease (SID). Data were extracted from the Humedica database (H-DB) and Guardian Research Network (GRN) database from October 1, 2015 to March 10, 2020, including a 6-month pre-index period (PIP) and 12-month follow-up. Patients aged ≥18 years diagnosed with chronic lymphocytic leukemia/small lymphocytic lymphoma, multiple myeloma, or non-Hodgkin's lymphoma in the PIP were stratified into 2 cohorts: SID (hypogammaglobulinemia [using ICD-10-CM codes] or serum IgG levels <5.0 g/L, both with signs and symptoms of SID or at least 1 infection) and no-SID. Patients with SID or primary immunodeficiency diseases in the PIP were excluded. Overall, 2221 patients with SID (H-DB/GRN: n = 1959/262), and 19,141 patients without SID (n = 17,598/1543) were included. Baseline characteristics were similar across cohorts. At 12-month follow-up, significantly more patients with SID had experienced ≥1 infection and ≥1 severe bacterial infection than those without SID (both P < .001). H-DB/GRN mean (standard deviation) number of severe bacterial infections was 7.6 (9.9)/2.9 (2.7) for the SID cohort versus 5.2 (6.8)/2.4 (2.2) for the no-SID cohort. This study confirms that patients with mature B cell malignancies and SID face a significantly higher burden of infections than those without SID.

1 January 2025 in Advances in Hematology
Verified
Journal Article
Open access
CSCsaba Siffel
Csaba Siffel
MDMatthew S. Davids
Matthew S. Davids
CAColin Anderson-Smits
Colin Anderson-Smits
MKMarta Kamieniak
Marta Kamieniak
KRKaili Ren
Kaili Ren
JRJoshua Richter
Joshua Richter
Patients with multiple myeloma (MM) and secondary immunodeficiency (SID) are at risk of infection‐related morbidity and mortality owing to the disease process and treatment toxicity. This retrospective cohort study used anonymized data from the Optum‐Humedica database (October 2015–March 2020) to assess the burden of infection in patients with MM and SID versus patients without SID. Patients aged ≥ 18 years with confirmed MM were assigned to SID and no‐SID cohorts using an algorithm considering serum IgG levels < 5.0 g/L, hypogammaglobulinemia diagnosis codes, and ≥ 1 major infection. Patients with SID were stratified into those treated or not treated with immunoglobulin replacement therapy (IgRT and no‐IgRT cohorts). At 12 months follow‐up, a greater proportion of the SID cohort than the no‐SID cohort experienced infections (58.9% vs. 31.3%; p < 0.001), severe infections (29.8% vs. 10.6%, p < 0.001), and infection‐related hospitalizations (26.9% vs. 9.1%; p < 0.001). Bacterial infections were the most common infection type (SID cohort, 49.2%; no‐SID cohort, 26.1%; IgRT cohort, 70.4%; no‐IgRT cohort, 45.1%). Use of anti‐infectives and healthcare resource utilization was higher in the SID cohort than in the no‐SID cohort. Median overall survival was shorter in the SID versus no‐SID cohort (12.6 vs. 14.7 months; p < 0.001) and was similar in the IgRT versus no‐IgRT cohort (8.5 vs. 12.5 months; p = 0.446). Among patients with MM and SID, the higher infection burden in patients treated with IgRT than no‐IgRT suggests the IgRT cohort was a more vulnerable population. A better understanding of SID burden may improve outcomes for patients with MM.